Merck KGaA (MRK) Stock Overview
Operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for MRK from our risk checks.
MRK Community Fair Values
Create NarrativeSee what 75 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €108.20 |
| 52 Week High | €131.65 |
| 52 Week Low | €100.70 |
| Beta | 0.80 |
| 1 Month Change | 0.74% |
| 3 Month Change | -14.02% |
| 1 Year Change | -11.24% |
| 3 Year Change | -34.18% |
| 5 Year Change | -23.37% |
| Change since IPO | 597.66% |
Recent News & Updates
MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance
Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.
MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside
Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.
MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside
Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.Recent updates
MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance
Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside
Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside
Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside
Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential
Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential
Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.MRK: Refined Earnings Outlook Points To Balanced Future Return Potential
Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.MRK: Future Earnings Power And HPC Expansion May Support Upside
Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead
Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.MRK: Margin Strength And AI Deal Will Drive Future Upside
Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.MRK: New Leadership Change And AI Partnership Will Drive Shares Higher
Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.MRK: Future CEO Appointment Will Support Recovery and Restore Confidence
The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.Global Biotechnology And Digital Automation Will Drive Future Healthcare
Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.Global Biotechnology And Digital Automation Will Drive Future Healthcare
Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
Jul 24
Merck KGaA's (ETR:MRK) Share Price Not Quite Adding Up
Jul 03
AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights
Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.Shareholder Returns
| MRK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.4% | -7.5% | -2.1% |
| 1Y | -11.2% | 9.6% | 1.7% |
Return vs Industry: MRK underperformed the German Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: MRK underperformed the German Market which returned 2.6% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MRK's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 59,077 | Belen Garijo Lopez | www.emdgroup.com |
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization.
Merck KGaA Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | €47.04b |
| Earnings (TTM) | €2.61b |
| Revenue (TTM) | €21.10b |
Is MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | €21.10b |
| Cost of Revenue | €8.67b |
| Gross Profit | €12.43b |
| Other Expenses | €9.82b |
| Earnings | €2.61b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | 6.00 |
| Gross Margin | 58.90% |
| Net Profit Margin | 12.36% |
| Debt/Equity Ratio | 39.5% |
How did MRK perform over the long term?
See historical performance and comparisonDividends
Does MRK pay a reliable dividends?
See MRK dividend history and benchmarks| Merck KGaA dividend dates | |
|---|---|
| Ex Dividend Date | Apr 27 2026 |
| Dividend Pay Date | Apr 29 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 2 days |
Does MRK pay a reliable dividends?
See MRK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/29 12:23 |
| End of Day Share Price | 2026/04/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merck KGaA is covered by 42 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Charles Pitman | Barclays |